Detalhe da pesquisa
1.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Oncology
; 102(3): 239-251, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729889